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Abstract
Background The role of somatic BRCA1/2 gene mutations in breast cancer is getting increasing attention in view of heredi-
tary disease. The medullary phenotype and triple negative intrinsic subtypes are often, but not exclusively encountered in 
BRCA1 germline mutated breast cancer, whilst for BRCA2, no association to specific histological features are known. In this 
study, we addressed the relationship between morphological medullary phenotype and BRCA1/2 somatic mutations in breast 
cancer without known positive family anamnesis.
Methods 32 clinically sporadic breast cancers with medullary features were analyzed for somatic BRCA1/2 mutations (all 
coding exons) with next-generation sequencing technology. Paraffin-embedded formalin-fixed breast cancer samples from 
all patients were analyzed.
Results Three of 32 tumors (9%) had pathogenic (ARUP class-5) BRCA1 gene alterations. Two of these pathogenic vari-
ants exhibited deletions leading to frameshift mutations (p.Glu23fs, p.Val1234fs), and the remaining single-nucleotid-
variant resulted in premature STOP codon (p.Glu60Ter). In one patient, the same pathogenic BRCA1 mutation was detected 
(p.Glu23fs) in normal breast tissue. Retrospective follow-up in two patients revealed a positive family history for breast 
cancer and consecutive germline mutation testing confirmed presence of BRCA1 mutations. No somatic pathogenic BRCA2 
mutations were detected.
Conclusions BRCA1 mutation testing may be useful in clinically sporadic breast cancer patients with medullary features to 
identify potential mutation carriers independently from intrinsic molecular subtype. Formalin-fixed paraffin-embedded cancer 
tissue can undergo testing within a routine molecular-diagnostic setting as a clinical BRCA1/2 mutation screening strategy.
Keywords Sporadic breast cancer · Medullary features · BRCA1/2 mutation · NGS
Introduction
Assessment of BRCA1/2 gene mutation status from forma-
lin-fixed paraffin-embedded (FFPE) tissue became a rou-
tine procedure for patients with high-grade serous ovarian 
cancer, as patients with evidence of such mutations are eli-
gible for therapies including the PARP inhibitor olaparib 
(Hennessy et al. 2010; Mafficini et al. 2016; Moschetta et al. 
2016; Muggia 2009; Oza et al. 2015). The role of BRCA1/2 
gene mutations in patients with breast cancer is also get-
ting more attention, with genetic counseling in view of a 
hereditary disease becoming a highly demanding field in 
patient care (Farrugia et al. 2008; Gonzalez-Angulo et al. 
2011; Gross et al. 2016; Kwon et al. 2010a, b). The major-
ity of BRCA1 mutated breast cancers are so-called “triple 
negative” or of “basal-type”. In contrast, not all “triple nega-
tive” breast cancer patients have a germline BRCA1/2 muta-
tion. The indication for BRCA1/2 mutation testing is mainly 
based on clinical criteria, other than on histomorphological 
features (Dabbs 2012; Lakhani et al. 2012; Lips et al. 2017).
The medullary phenotype of breast cancer, which is 
often but not exclusively encountered in BRCA1 germline 
mutation carriers, cannot reliably be used as an indication 
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for genetic testing. (Dabbs 2012; Lakhani et al. 2012; Lips 
et al. 2017). The current WHO classification on breast can-
cer defines medullary differentiation as invasive high-grade 
carcinomas exhibiting various amounts of lymphocytic 
infiltration typically lacking in situ components and show-
ing sharply demarcated edges towards the tumor periphery 
(Dabbs 2012; Lakhani et al. 2012; Lips et al. 2017). Overall 
survival of typical and atypical medullary breast carcinomas 
seem to be quite similar to each other, however, prognostic 
difference to ductal non-special type (NST) breast cancer 
is controversially reported in the literature (Dabbs 2012; 
Lakhani et al. 2012; Lips et al. 2017) (Mateo et al. 2016; 
Mavaddat et al. 2012). In case of BRCA2 mutations in breast 
cancer, suggestive morphological and prognostic features are 
even more unspecific and thus less helpful. A wide range of 
histological subtypes, mainly a luminal hormone receptor 
positive phenotype, can be seen in breast cancer patients 
with BRCA2 germline mutation (Dabbs 2012; Lakhani et al. 
2012; Lips et al. 2017).
In this study, we explored the relationship between a med-
ullary phenotype in a series of breast cancer patients without 
known positive family history and BRCA1/2 mutation status 
with next-generation sequencing (NGS) technology. We ana-
lyzed BRCA1/2 mutation status in 32 breast cancer patients 
with medullary features (Fig. 1). The thus found pathogenic 
mutations were retrospectively compared with non-tumorous 
tissue and/or available long-term follow-up data.
Materials and methods
Breast cancer patients
All tissue samples were retrospectively retrieved from the 
archives of the Department of Pathology and Molecular 
Pathology, University Hospital Zurich, Switzerland, encom-
passing a period of 1994–2015. We identified 32 breast 
cancer cases displaying medullary histological features as 
defined in the WHO 2012 as follows: all tumors had some 
or all of the following features as sharp circumscription or 
pushing peripheral areas, syncytial growth pattern, mainly 
high-grade nuclear morphology and at least focal prominent 
stromal and intratumoral lymphocytic infiltration (Figs. 2, 
3). Patients’ age varied from 31 to 85 years (mean age 
52.3 years). Tumor size varied from 1.2 to 6.5 cm (mean 
tumor size 2.44 cm). 16 of 32 cases (50%) were negative for 
estrogen and progesterone receptors and also for Her2 (triple 
negative intrinsic phenotype), 3 of 32 cases (9.3%) were 
Her2 positive and 13 of 32 cases (40.7%) were hormone 
receptor positive and Her2 negative. All patients under-
went either mastectomy or local wide excision with axillary 
lymph node dissection (Table 1). There was no history of 
ovarian cancer in this cohort, three patients had benign ovar-
ian cysts including also one mature teratoma.
The study is a part of a retrospective larger breast can-
cer study previously approved by the Ethical Committee 
Fig. 1  Flow chart of study 
design
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of the Canton Zurich (KEK-ZH-2012-553). For selected 
cases, required by the ethical approval, informed consents 
were obtained. All cases enrolled into the study cohort were 
anonymized for the study.
Determination of hormone receptors and Her2 
status
The hormone receptors (estrogen, ER and progesterone, PR) 
were determined in all cases using routine antibodies and 
pretreatment conditions. HER2 status was determined using 
the DAKO Herceptest, the Ventana CB11 and Ventana 45A 
antibodies. Manual pretreatment protocols or semi-automatic 
and automatic benchmark systems have been used. Detailed 
technologies for ER/PR and HER2 status evaluation have 
been published, previously (Varga et al. 2013, 2014).
Next‑generation sequencing (NGS)
For all NGS assays, representative cancer areas for the 
microdissection and DNA isolation were selected and 
marked by Z.V. on a freshly cut hematoxylin-eosin (HE) 
section. The marked tumor area was punched (length 
2–4 mm, diameter 0.6 mm) from the paraffin block and 
DNA was isolated using a Promega DNA purification 
kit (Promega, Wisconsin, USA). Isolated genomic DNA 
Fig. 2  Histological appearance 
of breast carcinoma with medul-
lary features. a, b Low-power 
view of an invasive breast 
cancer with medullary features 
showing abundant lymphocytic 
infiltration, serpentine-syntitial 
like tumor cell formation and 
sharp demarcation to tumor 
periphery, hematoxylin and 
eosin stain
Fig. 3  a, b High-power view of 
an invasive breast cancer with 
medullary features. Syntitial 
tumor cell formation exhibiting 
high nuclear polymorphism and 
mitotic figures. Hematoxylin 
and eosin stain
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was quantified using a fluorometric assay (Qubit, Thermo 
Fisher Scientific, Massachusetts, USA) and NGS libraries 
were amplified with the AmpliSeq Library Kit 2.0 and 
the Oncomine BRCA Assay (Thermo Fisher Scientific). 
Clonal amplification und sequencing was performed 
with Hi-Q chemistry on the Ion PGM platform accord-
ing to manufacturer’s requirements (Thermo Fisher Sci-
entific). NGS data was analyzed with the Torrent Suite 
v5.0.3 and the Ion Reporter v5.0 including the Oncomine 
BRCA workflow. NGS run metrics (on target reads, mean 
depth, uniformity) are summarized in Table 2. NGS reads 
were aligned to the reference genome hg19/GRCh37 and 
the transcripts for BRCA1 (NM_007300.3) and BRCA2 
(NM_000059.3). The detected variants were filtered to 
the coding exons and excluded if they were listed in the 
commonSNP database (minor allele frequency > 1%). 
Additionally, variants were excluded if they had variant 
allele frequencies < 4% and variant allele coverage < 50× 
(internal validation of sensitivity of AmpliSeq assays). To 
further validate the performance of the Oncomine BRCA 
panel, a mixing dilution experiment was performed con-
firming the sensitivity of the assay for SNVs and INDELs. 
After filtering, the variants were annotated to the COS-
MIC, dbSNP, and ARUP BRCA databases (http://arup.
utah.edu/datab ase/BRCA/). ARUP classification was done 
according to Plon et al. (2008): (1) (not pathogenic or of 
no clinical significance); (2) (likely not pathogenic or of 
little clinical significance); (3) (uncertain); (4) (likely 
pathogenic); and (5) (definitely pathogenic). To further 
classify the impact of unknown mutations on protein level, 
Table 1  Clinico-pathological features of the cohort
Case number Histological diagnosis Age (years) Grading Tumor 
size (cm)
ER PR HER2
IHC
HER2
FISH
1 NST with medullary features 39 G3 2.4 100% positive 100% positive Score 0 Not amplified
2 NST with medullary features 85 G3 1.7 5% positive 5% positive NA Not amplified
3 NST with medullary features 57 G3 1.9 Negative Negative Score 0 NA
4 NST with medullary features 50 G3 2.2 Negative Negative Score 0 NA
5 NST with medullary features 52 G3 1.2 Negative Negative NA Not amplified
6 NST with medullary features 39 G3 4 Negative Negative NA Not amplified
7 NST with medullary features 31 G3 2 Negative Negative IHC 0 NA
8 NST with medullary features 53 G3 1.2 Negative Negative Score 3+ Amplified
9 NST with medullary features 69 G3 2.6 Negative Negative NA NA
10 NST with medullary features 59 G3 2.6 Negative Negative NA NA
11 NST with medullary features 49 G3 1.2 Negative Negative NA Not amplified
12 NST with medullary features 60 G3 1.2 1% positive 1% positive NA Not amplified
13 NST with medullary features 49 G3 2.6 5% positive 5% positive NA Not amplified
14 NST with medullary features 50 G3 1 Negative Negative NA Not amplifed
15 NST with medullary features 48 G3 2,5 60% positive 2% positve Score 1+ Not amplified
16 NST with medullary features 65 G3 2.2 80% positive Negative Score 1+ Not amplified
17 NST with medullary features 49 G3 0.9 Negative Negative Score 0 Not amplified
18 NST with medullary features 36 G3 4.5 Negative Negative Score 0 Not ampified
19 NST with medullary features 56 G3 2.3 100% positive 10% positive Score 1+ Not amplified
20 NST with medullary features 43 G3 2.2 100% positive 100% positive Score 2+ Not amplified
21 NST with medullary features 45 G3 3.5 100% positive 50% positive Score 2+ Not amplified
22 NST with medullary features 44 G3 6.5 Negative Negative Score 1+ Not amplified
23 NST with medullary features 65 G3 6 100% positive 90% positive Score 1+ Not amplified
24 NST with medullary features 73 G3 5 100% positive 80% positive Score 2+ Not amplified
25 NST with medullary features 55 G3 1.2 Negative Negative Score 0 NA
26 NST with medullary features 36 G3 3 20% positive 10% positive Score 0 Not amplified
27 NST with medullary features 56 G3 2.2 100% positive 20% positive Score 1+ Not amplified
28 NST with medullary features 45 G3 2.6 100% positive 80% positive Score 3+ Amplified
29 NST with medullary features 54 G3 1.2 Negative negative Score 3+ Amplified
30 NST with medullary features 76 G3 0.6 Negative Negative Score 2+ Not amplified
31 NST with medullary features 47 G3 2.2 100% positive Negative Score 0 Not amplified
32 NST with medullary features 39 G3 1.8 Negative Negative Score 0 Not amplified
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SIFT (http://sift.jcvi.org/) and PolyPhen (http://genet ics.
bwh.harva rd.edu/pph/) were used.
Results
Three of 32 cases (9%) had definitely pathogenic germline 
BRCA1 mutations (ARUP class 5) which lead either to a 
frameshift or a STOP codon in the protein (Table 3). No 
pathogenic somatic BRCA2 mutations were observed.
The first patient (no. 6) was diagnosed with breast can-
cer at an age of 40 years. NGS-based BRCA1/2 testing 
showed a 5-basepair deletion (c.3700_3704delGTAAA) 
in exon 11 in the BRCA1 gene which lead to a frameshift 
at aminoacid position 1234 (p.Val1234fs). The mutation 
is registered in the databases ARUP, ClinVar (ID 37542) 
and dbSNP (rs80357609) to be pathogenic. A second inde-
pendent NGS library was prepared and sequenced which 
successfully validated the BRCA1 mutation p.Val1234fs. 
Retrospective follow-up search revealed a positive family 
history in this patient. Due to a contralateral breast cancer 
20 years after the initial diagnosis, the patient underwent 
germline BRCA1 mutation testing, revealing the same 
pathogenic mutation in BRCA1.
The second patient (no. 7) with a pathogenic BRCA1 
alteration had a nonsense mutation (c.178C>T) in exon 5 
in the BRCA1 gene leading to a STOP codon in the protein 
(p.Gln60Ter). This mutation is as listed as well in the data-
bases ARUP, ClinVar (ID 54349) and dbSNP (rs80357471) 
to be pathogenic. An independent NGS library was pre-
pared and sequenced which successfully validated the 
Table 3  Pathogenicitiy 
classification of detected 
mutation in the analyzed 32 
cases
RV case I II III IV V
1 – – – – –
2 – – – – –
3 – – – – –
4 – – – – –
5 – – – – –
6 – – – – BRCA1: p.Val1234fs
7 – – – – BRCA1: p.Gln60Ter
8 – – – – –
9 – – – – –
10 – – – – –
11 – – – – –
12 – – – – –
13 – – – – –
14 – BRCA2: 
p.Ile2490Thr
– BRCA2: 
p.Leu2654Val
–
15 – – – – –
16 – – – – –
17 BRCA2: p.Lys3326Ter – – – –
18 – – – – BRCA1: p.Glu23fs
19 – – – – –
20 – – – – –
21 BRCA1: p.Lys862Glu – – – –
22 BRCA2: p.Asp1420Tyr – – – –
23 – – – – –
24 – – – – –
25 BRCA2: p.Asp1420Tyr – – – –
26 – – – – –
27 BRCA1: p.Arg841Trp – – – –
28 – – – – –
29 – – – – –
30 – – – – –
31 – – – – –
32 – – – – –
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mutation. Subsequent germline BRCA1 mutation testing 
showed the same pathogenic mutation in BRCA1.
The third patient (no. 18) had as a deletion 
(c.68_69delAG) in the BRCA1 gene, leading to a frameshift 
in the protein (p.Glu23fs). Subsequent NGS analysis of cor-
responding normal breast tissue revealed the same mutation, 
suggesting a hereditary disease. In this patient, there was no 
positive family history of breast cancer. Due to the young 
age (37 years at initial diagnosis) and the triple negative 
phenotype with medullary features, genetic counseling and 
testing was recommended to the patient at the weekly inter-
disciplinary tumor board. Four years after initial diagnosis, 
however, no records about germline BRCA1/2 testing could 
be found.
Pathogenic mutations of the BRCA1 gene are illustrated 
in details in Fig. 4.
Fig. 4  Pathogenic mutations of 
the BRCA1 gene in patients 6, 
7 and 18
 Journal of Cancer Research and Clinical Oncology
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In six patients, benign, likely benign or mutations of 
unknown significance (VUS) were detected (ARUP class 
1–3).
In one patient (no. 14), two SNVs were detected in exon 
15 (p.Ile2490Thr) and 17 (p.Leu2654Val) of the BRCA2 
gene. The mutation in exon 15 showed an allele frequency 
of almost 100%, representing a homozygous SNP, which 
was further underlined by a dbSNP entry (rs11571707) 
with a minor allele frequency (MAF) of 1.9% in the human 
population. The same mutation is registered in ClinVar (ID 
96852) with conflicting interpretation of clinical signifi-
cance. However, these entries are benign (11 entries), likely 
benign (1 entry), and of uncertain significance (1 entry), 
suggesting a non-pathogenic impact. The second mutation 
in patient no. 14 was detected at low allele frequency of 
4%. Since this is at the limit of detection of our NGS sys-
tem, a second independent NGS library was prepared and 
sequenced. The mutation p.Leu2654Val was successfully 
verified with an allele frequency of 5%. Interestingly, this 
mutation is registered neither in COSMIC, dbSNP nor in 
the ARUP. The protein alteration prediction tools SIFT and 
PolyPhen revealed highly destabilizing (damaging) values 
of 0 and 0.87, respectively. Therefore, the exon 17 mutation 
in BRCA2 (p.Leu2654Val) was classified as VUS.
One nonsense mutation (patient no. 17) was detected at 
the 3-prime end in exon 27 of the BRCA2 gene, leading to 
a STOP codon (p.Lys3326Ter). This mutation is registered 
in the ARUP and the ClinVar database and was suggested 
to be clinically not significant (ARUP class 1) (Farrugia 
et al. 2008; Tavtigian et al. 2008), and benign (ClinVar ID 
38266), respectively. Additionally, the mutation is listed in 
the dbSNP database (rs11571833) with a minor allele fre-
quency (MAF) of 0.4% in the human population. The muta-
tion was not validated in an independent NGS library run, 
since it was assumed to be non-pathogenic.
Additional mutations which were assumed to be non-
pathogenic according to ClinVar and ARUP entries were 
detected in patient no. 21 (BRCA1, p.Lys862Glu), no. 22 
(BRCA2, p.Asp1420Tyr), no. 25 (BRCA2, p.Asp1420Tyr), 
and no. 27 (BRCA1, p.Arg841Trp). These mutations were 
not validated with an independent NGS run due to non-
pathogenicity either.
Discussion
We performed BRCA1/2 testing by next-generation sequenc-
ing in clinically sporadic breast cancer patients with med-
ullary like breast cancer and without known BRCA1 and 
BRCA2 mutations at presentation. Our study demonstrates 
that about nine percent of medullary like breast cancer 
patients without any known positive family history were 
BRCA1 gene mutation carriers, whereas no pathogenic 
somatic BRCA1/2 mutations could be found.
BRCA1/2 mutations regained clinical attention, as 
patients with high-grade serous ovarian carcinomas with 
pathogenic BRCA1/2 mutations displayed improved over-
all and recurrence-free survival if treated with platinum-
based therapy in combination with PARP inhibitors such 
as olaparib (Hennessy et al. 2010; Mafficini et al. 2016; 
Moschetta et al. 2016; Muggia 2009; Oza et al. 2015; Kwon 
et al. 2010; Muggia et al. 2011). Patients with BRCA1/2 
germline mutated serous ovarian cancers responded better to 
first-line chemotherapy in the metastatic setting in compari-
son with sporadic serous high-grade carcinomas (Hennessy 
et al. 2010; Mafficini et al. 2016; Moschetta et al. 2016; 
Muggia 2009; Oza et al. 2015; Kwon et al. 2010; Muggia 
et al. 2011). Furthermore, resistance to taxane containing 
regimens have been documented in serous high-grade ovar-
ian carcinomas displaying BRCA1/2 germline mutations 
(Hennessy et al. 2010; Mafficini et al. 2016; Moschetta 
et al. 2016; Muggia 2009; Oza et al. 2015; Kwon et al. 2010; 
Muggia et al. 2011).
The role of pathogenic BRCA1/2 mutations in breast can-
cer is currently not linked to specific therapies and is rather 
restricted to the choice for genetic counseling (Chalasani and 
Livingston 2013). The need for genetic counseling includ-
ing germ line BRCA1/2 testing in breast cancer patients is 
increasing, however, selection criteria remain mostly a posi-
tive family history additionally to breast cancers harboring 
a triple negative intrinsic phenotype (Kwon et al. 2010a, b; 
Chalasani and Livingston 2013). Specific histological signs 
only exist for germline mutations in BRCA1. Breast cancers 
arising in BRCA1 germ line mutation carriers are mostly 
triple negative, of younger patients (< 50 years), high-grade 
and display so-called medullary features. Medullary-type 
breast cancers are characterized by dense lymphocytic infil-
trate and pushing peripheral borders (Gonzalez-Angulo 
et al. 2011; Kwon et al. 2010a, b; Dabbs 2012; Lakhani 
et al. 2012; Chalasani and Livingston 2013). The frequency 
of BRCA1 gene allelic loss were reported to be more fre-
quent in ER negative than in ER positive sporadic breast 
cancer cases (39 vs 12%) (Rhiem et al. 2010). In unselected 
triple negative breast cancers, around 19% mutations were 
reported in the BRCA1/2 genes including also scattered 
somatic mutations (15% in BRCA and 3.9% in BRCA2 
genes) (Gonzalez-Angulo et al. 2011). Interestingly, there 
is lack of data on sporadic medullary carcinomas and its 
association with BRCA1 germline or somatic mutations. The 
6.25% frequency of BRCA1 frame shift mutations in our 
study is lower than reported frequencies in unselected tri-
ple negative breast cancers or in sporadic cases or in serous 
high-grade ovarian carcinomas without family history vary-
ing from 19 to 28%) (Gonzalez-Angulo et al. 2011; Rhiem 
et al. 2010) (Mafficini et al. 2016; Moschetta et al. 2016). 
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Whether this lower frequency is due to the relatively small 
number of cases in our cohort or to the fact that medul-
lary phenotype is alone not pathognomic enough to predict 
BRCA1 mutation status, needs to be validated in further 
studies. On the other hand, 40.7% of the cases were hormone 
receptor positive in our study, which is unusually high in 
comparison to classical triple negative phenotype of clas-
sical medullary breast carcinoma. The high proportion of 
hormone receptor positive cases might possibly reflect the 
histological variability of medullary differentiation in breast 
cancer and might also contribute to the low frequency of 
somatic BRCA1 mutations.
In selected triple negative breast cancer cases, 57% were 
found to have BRCA1 and 23% BRCA2 germ line mutations 
(Gonzalez-Angulo et al. 2011).
The term BRCAness, defined as DNA repair loss in the 
BRCA1/2 genes without germ line mutations, resulting in 
the same function loss and inactivation the BRCA1/2 genes, 
has been conflictingly discussed and addressed in the litera-
ture (Muggia 2009; Lips et al. 2017; Muggia et al. 2011; 
Chalasani and Livingston 2013; Vollebergh et al. 2014). 
Probably, the choice of technology for assessing the DNA 
damage as MPLA, qPCR, IHC or aCGH methodologies 
resulted in non-standardized definitions of what consists of 
BRCAness damage (Chalasani and Livingston 2013; Lips 
et al. 2017). In two studies, breast cancers with BRCA1-
like signature, as defined as BRCAness of the BRCA1 gene 
were found in 18% of breast cancers and showing a better 
response to anthacyline-based or platin containing high-dose 
chemotherapies (Lips et al. 2017; Vollebergh et al. 2014). 
One further study reported a higher frequency of BRCA2-
like signatures in hormone receptor positive breast cancer 
cases and also a better response to neoadjuvant chemother-
apy with anthracycline-based regiments (Lips et al. 2017). 
Which technology is the most reliable to predict clinical out-
come or the indication to genetic counseling in cases with 
BRCAness evidence is not solved at the current time and 
needs clinical validation in further studies (Muggia 2009; 
Muggia et al. 2011; Chalasani and Livingston 2013).
The current technology of next-generation sequencing 
in paraffin-embedded, formalin-fixed material was first 
described in ovarian high-grade serious cancer both for 
somatic and germ line mutations, providing a sensitivity 
of > 90% after verifying the data with Sanger sequencing 
(Mafficini et al. 2016). This technology became meanwhile 
standard in somatic BRCA1/2 testing in ovarian cancer and 
was also the choice of methodology in our study. The clas-
sification system for detected mutations using NGS and 
Sanger sequencing was recently defined by Eccles (Eccles 
et al. 2015). A five-tier score system, ranging from non- or 
likely non-pathogenic mutations (classes 1/2) through uncer-
tain significance as class 3 to likely or definitely pathogenic 
mutations (classes 4/5) is linked to recommendations in 
terms of clinical management and to assessing risk situa-
tion of the given patient (Eccles et al. 2015). Scores 4/5 are 
recommended as high-risk patient with appropriate genetic 
counseling, whilst classes 1 and 2 should follow manage-
ment based on family history alone. At the current time, no 
clear guidelines exist for the clinical management of genes 
of uncertain significance (class 3). (Farrugia et al. 2008; 
Plon et al. 2008; Tavtigian et al. 2008) (Eccles et al. 2015). 
In or study, we found three definitely pathogenic somatic 
mutations of the BRCA1 genes (class 5).
Based on the data in our cohort, medullary breast cancer 
phenotype without known family history in breast cancer, 
has a low frequency of somatic BRCA1 mutations, even 
though these mutations turned out to correlate with germ 
line mutations of the BRCA1 gene independently from other 
factors as younger age and triple negative intrinsic pheno-
type. These data might be of help in case genetic counseling 
in sporadic breast cancers with medullary features. On the 
other hand, medullary phenotype without family anamne-
sis did not have any class 4 or 5 somatic mutations in the 
BRCA2 gene, pointing out to the role of the BRCA1 gene 
only in breast cancer with medullary features. Our data need 
to be validated in further lager studies.
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